Gabapentin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Chronic Pain

• Pregabalin
• Celecoxib
• Diclofenac
• Duloxetine
• Ibuprofen
• Ketorolac
• Meloxicam
• Naproxen

Other medications in Mental Health

• Guanfacine
• Haloperidol
• Iloperidone
• Imipramine
• Isocarboxazid
• Levomilnacipran
• Lisdexamfetamine
• Lithium

What Gabapentin is approved for (FDA label)

Gabapentin Capsules are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin capsules are indicated for: Postherpetic neuralgia in adults ( 1 ) Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: September 11, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Gabapentin (FDA label)

Capsules Gabapentin Capsules, USP 400 mg are size '0' Hard gelatin capsules with orange opaque cap and orange opaque body, imprinted "400 mg" in blue ink on cap and "234" in blue ink on body, filled with white to off-white powder. Capsules: 400 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 4a975ebe-ae0a-446a-8a3d-2ca325e28f93. SPL document ID: 5b3aac21-ed90-1a17-e063-6394a90a6d3a. Label effective date: September 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Gabapentin (FDA label)

The following serious adverse reactions are discussed in greater detail in other sections: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions ( 5.1 )] Anaphylaxis and Angioedema [see Warnings and Precautions ( 5.2 )] Somnolence/Sedation and Dizziness [see Warnings and Precautions ( 5.4 )] Suicidal Behavior and Ideation [see Warnings and Precautions ( 5.5 )] Increased Risk of Seizures and Other Adverse Reactions with Abrupt or Rapid Discontinuation [see Warnings and Precautions ( 5.6)] Status Epilepticus [see Warnings and Precautions ( 5.7 )] Respiratory Depression [see Warnings and Precautions ( 5.8 )] Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age) [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (incidence ≥8% and at least twice that for placebo) were: Postherpetic neuralgia: Dizziness, somnolence, and peripheral edema ( 6.1 ) Epilepsy in patients >12 years of age: Somnolence, dizziness, ataxia, fatigue, and nystagmus ( 6.1 ) Epilepsy in patients 3 to 12 years of age: Viral infection, fever, nausea and/or vomiting, somnolence, and hostility ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 4a975ebe-ae0a-446a-8a3d-2ca325e28f93. SPL document ID: 5b3aac21-ed90-1a17-e063-6394a90a6d3a. Label effective date: September 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Gabapentin (FDA label)

Gabapentin capsules are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. Known hypersensitivity to gabapentin or its ingredients ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 4a975ebe-ae0a-446a-8a3d-2ca325e28f93. SPL document ID: 5b3aac21-ed90-1a17-e063-6394a90a6d3a. Label effective date: September 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Gabapentin (FDA label)

Drug Reaction with Eosinophilia and Systemic Symptoms (Multiorgan hypersensitivity): Discontinue if alternative etiology is not established ( 5.1 ) Anaphylaxis and Angioedema: Discontinue and evaluate patient immediately ( 5.2 ) Driving Impairment; Somnolence/Sedation and Dizziness: Warn patients not to drive until they have gained sufficient experience to assess whether their ability to drive or operate heavy machinery will be impaired ( 5.3 , 5.4 ) Suicidal Behavior and Ideation: Monitor for suicidal thoughts/behavior ( 5.5 ) Abrupt or rapid discontinuation may increase the risk for seizures. Withdrawal symptoms, or suicidal behavior and ideation have been observed after discontinuation ( 5.6 ) Respiratory Depression: May occur with gabapentin when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment.

Source: FDA prescribing information (DailyMed). Set ID: 4a975ebe-ae0a-446a-8a3d-2ca325e28f93. SPL document ID: 5b3aac21-ed90-1a17-e063-6394a90a6d3a. Label effective date: September 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Gabapentin (FDA label)

Concentrations increased by morphine; may need dose adjustment ( 5.4 , 7.1 ) 7.1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphine) [see Warnings and Precautions ( 5.8 )] . Hydrocodone Coadministration of gabapentin with hydrocodone decreases hydrocodone exposure [see Clinical Pharmacology ( 12.3 )]. The potential for alteration in hydrocodone exposure and effect should be considered when gabapentin is started or discontinued in a patient taking hydrocodone.

Source: FDA prescribing information (DailyMed). Set ID: 4a975ebe-ae0a-446a-8a3d-2ca325e28f93. SPL document ID: 5b3aac21-ed90-1a17-e063-6394a90a6d3a. Label effective date: September 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.